ARTICLE
31 December 2025

NSCEB Assesses Future Of U.S.-China Biotechnology Competition

BC
Bergeson & Campbell

Contributor

Bergeson & Campbell, P.C. is a Washington D.C. law firm focusing on chemical product approval and regulation, product defense, and associated business issues. The Acta Group, B&C's scientific and regulatory consulting affiliate provides strategic, comprehensive support for global chemical registration, regulation, and sustained compliance. Together, we help companies that make and use chemicals commercialize their products, maintain compliance, and gain competitive advantage as they market their products globally.
On December 19, 2025, the National Security Commission on Emerging Biotechnology (NSCEB) announced the publication of a paper entitled "The Future of U.S.-China Biotechnology Competition."
Worldwide Food, Drugs, Healthcare, Life Sciences
Bergeson & Campbell are most popular:
  • within International Law, Technology and Strategy topic(s)

On December 19, 2025, the National Security Commission on Emerging Biotechnology (NSCEB) announced the publication of a paper entitled "The Future of U.S.-China Biotechnology Competition." The paper notes that although the United States has historically led in biotechnology, over the past 20 years, China has systematically built a vertically integrated biotechnology ecosystem that is now in prime position to challenge U.S. leadership. According to the paper, China's new competitive posture "is propelled by strategy and policies implemented on top of a foundation of non-market practices and brute force economics." NSCEB states unless the United States "takes swift policy action, the Chinese Communist Party's whole-of-nation approach to biotechnology will further undercut the U.S. industry, sending jobs, research and discovery, and opportunities for industry growth to China." The paper continues NSCEB's analysis of the U.S.-China competition in biotechnology, establishing "a new benchmark documenting the empirical evidence of China's emerging lead, as well as the policy and investment mechanisms driving it."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More